AMWELL ANNOUNCES RESULTS FOR FIRST QUARTER 2024 Boston, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at to view the first quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at or by dialing 1-888-510-2008 for U.S. participants or...
Amwell Releases 2024 Corporate Responsibility Report Report demonstrates company progress toward enabling digital healthcare with purpose Boston, April 29, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced the release of its 2024 Corporate Responsibility Report, which details the company’s latest progress across environmental, social, and governance (ESG) topics and highlights Amwell’s growing positive impact on key stakeholders and the communities it serves. “Corporate responsibility is fundamental to our mission to transform healthcare, wh...
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an upd...
Amwell to Participate in Upcoming Investor Conference Boston, April 25, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference. Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day. An audio webcast of the fireside chat will be available at About Amwell Amwell is a leading hybrid care delivery enablement platform ...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024....
SeaChange Announces an Agreement to be Acquired by Enghouse and Termination of Previously Announced Proposed Acquisition by Partner One BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, has entered into an asset purchase agreement (the “Enghouse Purchase Agreement”) under which an affiliate of Enghouse Systems Limited (“Enghouse”), a leading global telecommunication technology and solutions company that prov...
Appian To Announce First Quarter 2024 Financial Results on May 2 MCLEAN, Va., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) today announced that it will release financial results for the first quarter ended March 31, 2024, before the U.S. financial markets open on Thursday, May 2, 2024. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can dial in the same way they alway...
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALS LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a bro...
SeaChange Announces a Second Amendment to Purchase Agreement with Partner One Along with Further Increased Purchase Price BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, has entered into a second omnibus amendment (such amendment, “Amendment No. 2”) to the asset purchase agreement and software purchase agreement (the “Original Purchase Agreements”) previously announced on March 11, 2024, as amended by the ...
Amwell® to Report First Quarter 2024 Operating Results May 1 Boston, April 17, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, will report its first quarter 2024 operating results Wednesday, May 1. Following the distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The audio webcast can be accessed by visiting the of the company's website. Alternatively, participants can call (888) 510-2008...
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate c...
SeaChange Announces an Amended Purchase Agreement with Partner One Along with an Increased Purchase Price as Go-Shop Period Ends BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, has entered into an omnibus amendment (such amendment, the “Amendment to the Purchase Agreements”) to the previously announced asset purchase agreement and software purchase agreement (the “Original Purchase Agreements”) with affili...
Allogene Therapeutics Announces Q2 Investor Conference Participation SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9...
Appian to Host Investor Day at Appian World on April 16 MCLEAN, Va., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) announced today that it will host its Investor Day on Tuesday, April 16, 2024 at 1:30 p.m. Eastern Time. The event will take place during Appian World, the company's annual customer conference. A live webcast of the event will be available under the "News and Events " section of the Company's investor relations website at . About AppianAppian is a software company that automates business processes. The Appian AI Platform includes everything you need to design, automate...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany explori...
Amwell Receives Continued Listing Standard Notice From NYSE Amwell’s Class A Common Stock continues to trade on the NYSE Boston, April 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of healthcare software as a service, today announced that it received a notice on April 2, 2024 from the New York Stock Exchange (NYSE) informing the company that it is not in compliance with the NYSE’s continued listing minimum price criteria with respect to its Class A common stock because the average closing price of the company’s Class A common stock was less than $1 per share over...
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms for Mydcombi at the Vision Source Exchange, April 10-13, in Orlando NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the comp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.